Swedish biotech company Axelar has reported preliminary interim results of its Phase II study indicating AXL-003’s efficacy as a second-line treatment for patients with non-small cell lung cancer (NSCLC).
The randomised open-label study compares AXL1717 with docetaxel in patients with previously treated, locally advanced or metastatic NSCLC.
The primary endpoint is progression free survival (PFS) after 12 weeks.
Axelar CEO Dr Carl Harald Janson said AXL1717 demonstrated a positive impact in the difficult-to-treat patient population.
"The encouraging trial data provides a platform for the further development of AXL1717. I look forward to finalising this trial and preparing for the next step in development," Janson said.
According to preliminary analysis, AXL1717 rate of PFS is similar to docetaxel after 12 weeks. The most frequent serious adverse events include cases with neutropenia occurring in both treatment regimes.
The company finalised the trial to have 100 patients instead of the planned 140, on the basis of the interim data.
97 patients who were previously enrolled will be continue treatment and will be monitored in the study.
Karolinska Development CEO Dr Torbjörn Bjerke said; "Based on these interim results, we believe that AXL1717 has the potential to become an important part of future treatment options available to clinicians as well as a valuable asset for Karolinska Development."